First half trading significantly stronger

In a statement to accompany today’s AGM, Eco Animal Health reports that trading in the first half of FY26 “has been significantly stronger compared to the same period last year” despite “currency headwinds and tariff challenges”. Revenue is seen over 15% ahead year-on-year (H1 2025: £33.2m), i.e. indicative of c.£38m, with particular strength seen in the China/Japan segment (over 40%YoY growth) and North America (over 25% YoY growth). The Group also expects to report improved gross margins for the period, resulting in a “material increase in adjusted EBITDA” compared to H1 25 (£0.45m).

Whilst EAH’s enteric and respiratory antibiotic Aivlosin^® remains the driver of performance, the cash it generates continues to fuel the Group programme for development of novel next-generation treatments. Following recent regulatory filings in Europe for the first of products in the pipeline, mycoplasma poultry vaccine ECOVAXXIN^® MS, we expect further submissions in the coming 12 months, with up to 9 products expected to receive US and EU approval in the next 5-6 years.

In our view, Eco Animal Health’s valuation continues to underplay the well-funded investment in its new product range and their future value: our Fair Value is 136p/share.